Down-Regulation of CYP3A4 by the K
Akt-Nrf2
CYP3A4
Ca2+-activated K+ channel
KCa1.1
cancer spheroid
doxorubicin resistance
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Oct 2023
27 Oct 2023
Historique:
received:
10
10
2023
revised:
26
10
2023
accepted:
26
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
The large-conductance Ca
Identifiants
pubmed: 37958656
pii: ijms242115672
doi: 10.3390/ijms242115672
pmc: PMC10648085
pii:
doi:
Substances chimiques
CYP3A4 protein, human
EC 1.14.14.55
Cytochrome P-450 CYP3A
EC 1.14.14.1
Cytochrome P-450 Enzyme System
9035-51-2
Doxorubicin
80168379AG
NF-E2-Related Factor 2
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
KCNMA1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP20K07071
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Oncotarget. 2020 May 26;11(21):1988-2001
pubmed: 32523653
Pharmacol Res. 2021 Nov;173:105853
pubmed: 34455076
Drug Metab Dispos. 2002 Apr;30(4):438-45
pubmed: 11901098
Onco Targets Ther. 2022 Jul 20;15:783-797
pubmed: 35899081
Oxid Med Cell Longev. 2020 Jan 3;2020:3028387
pubmed: 31998435
Chem Biol Interact. 2013 Oct 25;206(1):100-8
pubmed: 23994249
Dev Growth Differ. 2022 Dec;64(9):527-536
pubmed: 36251346
Nature. 2016 Sep 22;537(7621):539-543
pubmed: 27626381
Curr Drug Metab. 2022;23(3):242-250
pubmed: 35331105
J Pharm Pharmacol. 2011 Feb;63(2):214-21
pubmed: 21235585
Leukemia. 2007 Mar;21(3):427-38
pubmed: 17215852
Cancer Sci. 2021 Sep;112(9):3769-3783
pubmed: 34181803
Cancers (Basel). 2011 Mar 22;3(1):1467-79
pubmed: 24212669
Cancer Chemother Pharmacol. 2019 Sep;84(3):487-499
pubmed: 31309254
BMC Cancer. 2019 Aug 1;19(1):757
pubmed: 31370818
Oncogenesis. 2021 Jan 19;10(1):12
pubmed: 33468992
Curr Drug Metab. 2007 Feb;8(2):185-94
pubmed: 17305497
FEBS Lett. 2016 Dec;590(23):4372-4380
pubmed: 27800604
Cancer Cell. 2018 Jul 9;34(1):21-43
pubmed: 29731393
Trends Pharmacol Sci. 2020 Aug;41(8):503-506
pubmed: 32571525
Int J Mol Sci. 2014 Dec 09;15(12):22743-56
pubmed: 25501330
Life Sci. 2021 Aug 1;278:119527
pubmed: 33887349
Antioxidants (Basel). 2021 Feb 26;10(3):
pubmed: 33652780
Int J Mol Sci. 2023 Aug 29;24(17):
pubmed: 37686184
BMC Cancer. 2019 Jun 24;19(1):618
pubmed: 31234823
Front Oncol. 2021 Jun 28;11:662135
pubmed: 34262860
Biochem Pharmacol. 2015 Jan 1;93(1):92-103
pubmed: 25451687
Front Cell Dev Biol. 2021 Oct 28;9:690306
pubmed: 34778245
Biochem Pharmacol. 2010 Feb 1;79(3):373-80
pubmed: 19766599
Front Oncol. 2023 Jan 10;12:1074469
pubmed: 36703789
Int J Mol Sci. 2018 Aug 18;19(8):
pubmed: 30126198
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
J Cell Physiol. 2021 Apr;236(4):2443-2458
pubmed: 32960465
Front Oncol. 2022 Apr 19;12:880077
pubmed: 35515121
Int J Mol Sci. 2021 Dec 17;22(24):
pubmed: 34948357
J Clin Lab Anal. 2021 Aug;35(8):e23817
pubmed: 34114685
Crit Rev Oncol Hematol. 2023 Feb;182:103920
pubmed: 36702423
Pathol Res Pract. 2022 Sep;237:154010
pubmed: 35843034
Drug Metab Dispos. 2018 Apr;46(4):397-404
pubmed: 29440179
Antioxid Redox Signal. 2023 Apr;38(10-12):853-876
pubmed: 36242099
Nutr Cancer. 2019;71(6):1007-1018
pubmed: 31032633
Life Sci. 2019 Dec 15;239:116986
pubmed: 31678283
Genes (Basel). 2022 Oct 29;13(11):
pubmed: 36360213
FEBS J. 2021 May;288(9):2784-2835
pubmed: 32810346
Cancers (Basel). 2022 Oct 25;14(21):
pubmed: 36358647
Adv Pharmacol. 2018;83:3-32
pubmed: 29801580
Int J Mol Sci. 2022 Aug 03;23(15):
pubmed: 35955737
J Biochem. 2022 May 11;171(5):567-578
pubmed: 35137113